Investment
Features
FeesSafety
Academy
More
Pluang+

Rigel licenses FDA-approved breast cancer drug VEPPANU, aiming to boost growth with new treatment option.

Company Fundamentals
12 May 2026
PRNewsWire
View Source
Bullish
pluang ai news

Rigel Pharmaceuticals has secured exclusive global rights to develop, manufacture, and commercialize VEPPANU (vepdegestrant), the first FDA-approved oral PROTAC for advanced ER+/HER2-, ESR1-mutated breast cancer. The drug showed a significant progression-free survival benefit in Phase 3 trials, doubling median PFS compared to fulvestrant. Rigel plans to leverage its commercial infrastructure to accelerate revenue growth, paying $70 million upfront plus potential milestones to Arvinas and Pfizer. The deal, pending regulatory clearance, positions VEPPANU as a key growth driver in Rigel's oncology portfolio.

More News (PFE)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App